Topical Polymyxin B/Neomycin Combination for Superficial Skin Infections
For mild-to-moderate superficial skin infections, topical polymyxin B/neomycin combination ointments (typically as triple-antibiotic with bacitracin) are effective and recommended for preventing infection in minor wounds and traumatic injuries, but are NOT indicated for established skin and soft tissue infections requiring systemic therapy.
Clinical Context and Appropriate Use
The polymyxin B/neomycin combination is FDA-approved for topical use in preventing and treating superficial infections 1. However, the IDSA guidelines make clear distinctions about when topical versus systemic antibiotics are appropriate 2:
When Topical Antibiotics ARE Appropriate:
- Minor traumatic wounds (lacerations, abrasions) being repaired or managed in outpatient/ED settings
- Prevention of surgical site infections in clean wounds healing by primary intention
- Superficial wound contamination without systemic signs
Evidence strongly supports this use: topical antibiotics reduce SSI risk by 39% compared to no antibiotic (RR 0.61,95% CI 0.42-0.87; NNTB = 50) and by 51% compared to antiseptics (RR 0.49,95% CI 0.30-0.80; NNTB = 24) 3. The neomycin/polymyxin B/bacitracin combination specifically eliminates bacterial contamination within 16-24 hours and accelerates healing (mean 9 days) 4.
When Topical Antibiotics Are NOT Appropriate:
The IDSA guidelines explicitly state that for established skin and soft tissue infections (cellulitis, abscesses, furuncles), systemic antibiotics—not topical agents—are required 2:
- Purulent infections (abscesses, furuncles): Require incision and drainage; systemic antibiotics only if fever, systemic signs, or extensive surrounding cellulitis (>5 cm erythema) present
- Non-purulent infections (cellulitis): Require oral or IV systemic antibiotics active against streptococci ± MRSA depending on severity
- Surgical site infections: Opening the wound is primary therapy; antibiotics unnecessary if minimal systemic signs (temp <38.5°C, WBC <12,000, pulse <100) 2
Specific Recommendations
Application Protocol:
- Apply twice daily to clean wounds
- Cover with occlusive dressing after application
- Continue for 5-10 days or until complete epithelialization 4, 5
Efficacy Data:
The combination demonstrates infection rates of 4.5-5.5% versus 17.6% for petrolatum control (p=0.0034) in ED-repaired wounds 5. It remains effective against common skin pathogens without readily developing resistance 6, 7.
Critical Caveats:
Allergic Contact Dermatitis Risk: While studies show low rates, neomycin sensitization can occur. The evidence is insufficient to quantify exact risk (RR 3.94,95% CI 0.46-34.00; very low quality) 3. Monitor for local reactions.
Antibiotic Resistance Concerns: Current evidence shows stable susceptibility patterns 6, but avoid indiscriminate use in established infections where systemic therapy is indicated.
Not a Substitute for Proper Wound Care: High-pressure irrigation, debridement when necessary, and appropriate closure technique remain fundamental 5.
Algorithm for Decision-Making:
Is this a minor traumatic wound or surgical incision healing by primary intention?
- YES → Consider topical polymyxin B/neomycin combination
- NO → Proceed to step 2
Are there signs of established infection (purulence, cellulitis, systemic signs)?
- YES → Systemic antibiotics required; topical agents insufficient 2
- NO → Topical prophylaxis appropriate
Any contraindications (known neomycin allergy, large surface area)?
- YES → Use alternative (bacitracin alone or petrolatum)
- NO → Apply twice daily with occlusive dressing
The fundamental principle: topical polymyxin B/neomycin combinations are prophylactic/adjunctive agents for minor wounds, not treatment for established skin and soft tissue infections requiring systemic therapy 2, 3.